Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Mar 11 · below the Ichimoku cloud · RSI 41 · MACD below its signal
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $56.0K | 0.00% | 12.91K | −0.8% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a YI trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| May 26, 2026 | Chen Yang YangDirector | Sale at price 5.33 - 5.40 per share. | 4.8K | $26.04K |
| May 11, 2026 | Luo Jun JustinDirector | Stock Award(Grant) at price 0.00 per share. | 810.3K | — |
| May 11, 2026 | Chen Yang YangDirector | Stock Award(Grant) at price 0.00 per share. | 594.2K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 185.2 | 8.4 | -17.6 | -4.9 | -14.8 | -17.8 | -11.3 | -14.3 | 3.9 | -7.6 | +23.8% | ||
| 2025 | 838.7 | 52.4 | -8.6 | 2.0 | -1.2 | -12.6 | -3.8 | -6.4 | -29.2 | -4.0 | -15.1 | -31.0 | +312.9% |
| 2024 | -11.6 | 0.0 | -15.3 | -10.3 | 13.5 | -9.3 | 7.5 | -33.0 | -1.3 | -3.9 | 13.7 | -25.3 | −60.0% |
| 2023 | 1.0 | -11.1 | -2.2 | 3.0 | -8.8 | -1.2 | 29.3 | -20.1 | 2.4 | -15.8 | -9.1 | -22.1 | −48.7% |
| 2022 | -13.4 | -11.9 | -0.4 | -26.3 | 2.0 | 3.0 | 37.9 | 3.2 | -8.5 | 0.7 | 10.7 | 1.0 | −13.7% |
| 2021 | 58.6 | 77.3 | -29.4 | -9.7 | -21.9 | -6.6 | -35.2 | 4.4 | 0.3 | -15.7 | -26.0 | -9.1 | −49.6% |
| 2020 | -17.5 | 17.3 | 1.5 | 15.0 | -2.6 | -14.2 | 1.9 | -4.8 | 0.6 | 11.9 | 2.4 | -2.3 | +3.3% |
| 2019 | 42.5 | -0.6 | -25.4 | 25.6 | -2.9 | -29.7 | -29.9 | -32.1 | 83.8 | -4.3 | 9.7 | 31.7 | +9.6% |
| 2018 | -34.3 | 7.0 | -35.4 | −54.6% |
No analyst coverage for this instrument.
111, Inc., together with its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates through two segments, B2C and B2B. The company offers supply chain integration services that help pharmaceutical companies manage products through online and offline channels; product promotion, customer analytics, patient education, and brand awareness services; and marketing and channel data services. It also provides 1 Pharmacy online wholesale pharmacy that offers pharmaceutical and other health and wellness products; and 1 Medicine Marketplace online retail pharmacy that provides drugs, nutritional supplements, medical supplies and devices, personal care, and baby products. In addition, the company offers online loan application services; cloud-based inventory management services; smart procurement services, which collect pharmacies' historical purchase orders and inventory data; and Hawkeye automated salesforce tool, as well as online consultation, e-prescription, and data services. Further, its pharmacies provide drugs, including prescription and over-the-counter drugs comprising Western and Chinese medicines; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices that consists of bandages and thermometers; and personal care products that include skin care, birth control, sexual wellness, and baby products. Additionally, the company offers research and development, and consulting services; warehousing, procurement, and logistics services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies, medical professionals, and marketplace sellers. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.